Compare NMG & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NMG | CTMX |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 592.4M | 642.2M |
| IPO Year | 2015 | 2015 |
| Metric | NMG | CTMX |
|---|---|---|
| Price | $1.45 | $3.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $5.75 | ★ $12.10 |
| AVG Volume (30 Days) | 848.5K | ★ 3.8M |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $76,201,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.61 |
| P/E Ratio | ★ N/A | $22.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.37 | $1.72 |
| 52 Week High | $6.06 | $8.21 |
| Indicator | NMG | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 31.51 | 45.83 |
| Support Level | N/A | $3.06 |
| Resistance Level | $2.42 | $3.49 |
| Average True Range (ATR) | 0.09 | 0.16 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 13.89 | 83.33 |
Nouveau Monde Graphite Inc is a mineral exploration company. The company specializes in the exploration, evaluation, and development of mineral properties located in Quebec and is developing a natural graphite-based anode material that would qualify as battery-grade material to supply the lithium-ion industry. The Company currently operates in two segments: the Mining projects (which includes the Matawinie Mine project and the Uatnan Mining Project) and the Battery Material Plant project.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.